Early ADME in Phase 1 with BioMICADAS™
Use of low radiation ADME enables earlier, faster human knowledge with unparalleled accuracy using very small quantities of radiolabel.
In addition, Vitalea offers the following hybridized approach to ADME where we cover the full range of 14C concentrations using AMS and Liquid Scintillation Counting. Our scientists have many years of experience in merging the two platforms to deliver seamless results and cost efficiencies to our sponsors.
A low radiation, therapeutically relevant ADME study performed in Phase 1 testing maximizes value by delivering key human knowledge early and reliably, indicating human-specific issues at an early phase of development. This is only possible through the extreme sensitivity of the BioMICADAS™ Accelerator Mass Spectrometer (AMS), which provides sensitivity 10,000 greater than prior methods for ADME studies.
Key Information Obtained Early
Delivers Quickly and Cost Effectively
Delivers the Human Component of FDA (MIST) Guidance
A significant application for AMS in early ADME studies is to establish knowledge of human metabolites and physiochemistry in relation to safety species. Vitalea enables human ADME to be performed with accuracy and precision in a cost-effective model, meeting FDA guidance expectations - "Metabolites in Safety Testing" (2008).
|© 2012 Eckert & Ziegler Vitalea Science, Inc.||
2121 2nd Street B101, Davis CA 95618 · 530-341-0200 · email@example.com
A subsidiary of Eckert & Ziegler Isotope Products
|Credits | Contact | Home|